Nasopharyngeal and serological anti SARS-CoV-2 IgG/IgA responses in COVID-19 patients

  1. Bernadette Crescenzo-Chaigne
  2. Sylvie Behillil
  3. Vincent Enouf
  4. Nicolas Escriou
  5. Stephane Petres
  6. Marie Noelle Ungeheuer
  7. Jade Ghosn
  8. Sarah Tubiana
  9. Lila Bouadma
  10. Sylvie van der Werf
  11. Caroline Demeret

Reviewed by

Read the full article See related articles

Discuss this preprint

Start a discussion What are Sciety discussions?

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1016/j.jcvp.2021.100041
  2. ScreenIT

    SciScore for 10.1101/2021.01.13.20249038: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Institutional Review Board StatementConsent: This study was conducted with the understanding and the consent of each participant or its surrogate.
    IRB: Ethics approval was obtained from the French Ethic Committee CPP-Ile-de-France VI (ID-RCB: 2020-A00256-33).
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.
    Sex as a biological variablenot detected.

    Table 2: Resources

    Antibodies
    SentencesResources
    Study design: The objective of this study was to analyse the levels of anti-N SARS-CoV-2 IgA and IgG antibodies in the NPS and in the plasma of four confirmed COVID-19 cases with different clinical histories.
    anti-N SARS-CoV-2 IgA
    suggested: None
    IgG antibodies in the NPS and in the plasma of four confirmed COVID-19 cases with different clinical histories.
    suggested: None

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

    Results from TrialIdentifier: We found the following clinical trial numbers in your paper:

    IdentifierStatusTitle
    NCT04262921RecruitingFrench COVID Cohort

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2021.01.13.20249038 on medRxiv